NovaBay Pharmaceuticals, Inc.
5980 Horton Street
NovaBay Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of products: Aganocide® compounds and NeutroPhase®. Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides possess a very low likelihood that bacteria or viruses will be able to develop resistance, which is critical for advanced anti-infectives. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, NVC-422 is suited to treat and prevent a wide range of local, non-systemic infections. NovaBay’s clinical development activities are focused on three disease areas: Dermatology, Ophthalmology and Urology.
NovaBay has entered into a licensing and research collaboration agreement with Galderma S.A., a global leading pharmaceutical company dedicated exclusively to the field of dermatology. NovaBay is also developing NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care. NovaBay believes that NeutroPhase is the only patented pure hypochlorous acid solution available which has the potential to be best suited to treat the six-million-patients in the U.S. who suffer from chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers.